BioCryst Pharmaceuticals | BCRX - Equity Capital And Reserves


BioCryst Pharmaceuticals reported $-119.15M in Equity Capital and Reserves for its fiscal quarter ending in December of 2025.





Equity Capital And Reserves Change Date
Alnylam Pharmaceuticals USD 1.08B 286.2M Mar/2026
BioCryst Pharmaceuticals USD -119.15M 268.74M Dec/2025
Chugai Pharma JPY 2.03T 135.62B Dec/2025
Daiichi Sankyo JPY 1.71T 57.86B Dec/2025
DBV Technologies USD 168.77M 115.92M Dec/2025
Enanta Pharmaceuticals USD 126.59M 61.87M Dec/2025
Gilead Sciences USD 22.62B 1.16B Dec/2025
GlaxoSmithKline GBP 17.42B 1.05B Mar/2026
Glaxosmithkline GBP 22.06B 360M Dec/2025
Incyte USD 5.62B 455.37M Mar/2026
Ionis Pharmaceuticals USD 491.41M 2.32M Mar/2026
Karyopharm Therapeutics USD -292.93M 23.67M Dec/2025
Neurocrine Biosciences USD 3.41B 154.3M Mar/2026
Novavax USD -127.75M 28.92M Dec/2025
PTC Therapeutics USD -205.31M 49.56M Dec/2025
Regeneron Pharmaceuticals USD 31.42B 166.7M Mar/2026
Roche Holding CHF 33.8B 758M Dec/2025
Sarepta Therapeutics USD 1.14B 179.5M Dec/2025
Ultragenyx Pharmaceutical USD -80M 89.16M Dec/2025
Vertex Pharmaceuticals USD 19.36B 696.1M Mar/2026